EGFR and adenocarcinoma: Encouraging new treatments [including epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), anaplastic lymphoma kinase inhibitors, pemetrexed and bevacizumab for adenocarcinomas] have benefited specific patients with advanced or recurrent NSCLC (9–15).